Experts Make the Case for Improved Patient Care in Single-Chamber ICD and CRT-D Therapy with Pioneering DX Technology
Renowned Physicians Discuss Clinical Study Outcomes in Patients Benefiting from Single-Chamber ICDs Enhanced with Atrial Diagnostics, and from Two-lead CRT-D
BIOTRONIK has announced a satellite symposium taking place at this week’s European Heart Rhythm Association’s (EHRA) online congress: ‘Less is more: Do we still need an atrial lead for atrial sensing?’. Expert physicians will discuss key outcomes from the SENSE trial1, the THINGS2 and QP ExCELs3 registries; the event will be chaired by renowned cardiologist, Prof. Em. Pedro Brugada.
When patients do not require atrial pacing, a technology solution such as DX – which delivers atrial sensing without an atrial lead – can provide better and earlier atrial fibrillation diagnostic1-2 while still maintaining the simplicity of a single-lead device implantation4.
“I believe that with the combination of the DX technology and the automatic Home Monitoring, in terms of safety for our patients, there is no other system that can compete against that.” said Prof. Em. Pedro Brugada, University of Brussels, who will chair the event.
“When you consider the new atrial fibrillation guidelines, having atrial rhythm monitoring after you have detected AF is essential in assessing AF burden,” said Prof. Reza Wakili, University Hospital Essen in Germany, who will discuss insights from SENSE and THINGS in sub-clinical AF early diagnosis, and clarify the profile of patients who can benefit the most from the DX technology.
“With improved diagnosis of atrial fibrillation, even non-clinical, a significant reduction in the cost of management for stroke and heart failure events can be achieved. Significant savings can also be gained by halving the complication rate related to three-lead use in CRT,” said Dr. Mauro Biffi, University of Bologna, Italy. Dr. Biffi will discuss the benefits of DX technology in the context of cardiac resynchronization patients (CRT) and will address the question: “can we achieve cardiac resynchronization with only two leads?”.
EVENT DETAILS | Less is more: Do we still need an atrial lead for atrial sensing?
- When: Saturday, April 24, 2021
- Time: 9.30 – 10:00 am (Central European Summer Time)
- Chairman: Prof. Em. Pedro Brugada, University of Brussels
- Dr. Mauro Biffi, University of Bologna, Italy
- Prof. Reza Wakili, University Hospital Essen, Germany
- How to register: To get access to our session, you will first need to register for the EHRA 2021 – Online Congress https://www.escardio.org/Congresses-&-Events/EHRA-Congress/Registration . You will then be able to access our DX satellite symposium, which can be viewed in the scientific program section by clicking here (https://digital-congress.escardio.org/EHRA-Congress/sessions/633-less-is-more-do-we-still-need-an-atrial-lead-for-atrial-sensing )
DX technology is available in a DF4 connector with the Plexa ProMRI S DX lead, in Acticor/Rivacor devices - the latest generation of ICDs and CRT-Ds. It’s also available in a DF-1 connector on Intica Neo/Ilivia Neo and on former device generations.
- Thomas G et al. Subclinical atrial fibrillation detection with a floating atrial sensing dipole in single lead implantable cardioverter‐defibrillator systems: Results of the SENSE trial. J Cardiovasc Electrophysiol. 2019; 30: 1994‐ 2001.
- Biffi M et al. The role of atrial sensing for new-onset atrial arrhythmias diagnosis and management in single-chamber implantable cardioverter-defibrillator recipients: Results from the THINGS registry. J Cardiovasc Electrophysiol. 2020; 31: 846– 853.
- Shaik, NA et al. Novel two‐lead cardiac resynchronization therapy system provides equivalent CRT responses with less complications than a conventional three‐lead system: Results from the QP ExCELs lead registry. J Cardiovasc Electrophysiol. 2020; 31: 1784– 1792.
- Kurt M, Jathanna N, Babady M, et al. Avoiding inappropriate therapy of single‐lead implantable cardioverter‐defibrillator by using atrial‐sensing electrodes. J Cardiovasc Electrophysiol. 2018;29:1682‐1689. https://doi.org/10.1111/jce.13736
BIOTRONIK is a leading medical device company that has been developing trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, BIOTRONIK innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries